Kornitzer Capital Management Inc. KS boosted its holdings in Becton Dickinson and Co (NYSE:BDX) by 32.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,183 shares of the medical instruments supplier’s stock after buying an additional 3,679 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Becton Dickinson and were worth $3,841,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in the stock. TRUE Private Wealth Advisors acquired a new stake in shares of Becton Dickinson and during the second quarter valued at about $25,000. Allworth Financial LP boosted its stake in shares of Becton Dickinson and by 386.4% during the third quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 85 shares in the last quarter. Northwest Investment Counselors LLC acquired a new stake in shares of Becton Dickinson and during the third quarter valued at about $27,000. Hexavest Inc. acquired a new stake in shares of Becton Dickinson and during the second quarter valued at about $28,000. Finally, Lipe & Dalton acquired a new stake in shares of Becton Dickinson and during the second quarter valued at about $28,000. 84.29% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently commented on BDX shares. ValuEngine lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Wells Fargo & Co lowered their price objective on Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Wednesday. Morgan Stanley raised their price objective on Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 16th. Finally, Piper Jaffray Companies lowered their price objective on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Five research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and has an average rating of “Buy” and an average price target of $266.09.
Shares of BDX traded up $0.22 during mid-day trading on Friday, reaching $244.79. 1,479,428 shares of the company were exchanged, compared to its average volume of 1,173,922. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $264.74. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.67 and a current ratio of 1.19. The stock has a market capitalization of $66.59 billion, a PE ratio of 20.96, a PEG ratio of 1.62 and a beta of 1.09. The business has a 50 day simple moving average of $251.93 and a two-hundred day simple moving average of $246.89.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.30 by $0.01. Becton Dickinson and had a return on equity of 15.51% and a net margin of 6.84%. The company had revenue of $4.58 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same period last year, the company earned $2.93 earnings per share. The firm’s revenue was up 4.1% compared to the same quarter last year. On average, analysts predict that Becton Dickinson and Co will post 12.58 EPS for the current year.
In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 11,532 shares of Becton Dickinson and stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $260.38, for a total value of $3,002,702.16. Following the completion of the sale, the chief executive officer now directly owns 218,671 shares in the company, valued at $56,937,554.98. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP James C. Lim sold 9,299 shares of Becton Dickinson and stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $263.53, for a total value of $2,450,565.47. Following the completion of the sale, the executive vice president now owns 33,041 shares of the company’s stock, valued at $8,707,294.73. The disclosure for this sale can be found here. Insiders have sold 32,174 shares of company stock valued at $8,354,013 over the last 90 days. 0.12% of the stock is owned by corporate insiders.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: What is the formula for the cash asset ratio?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.